Rozanolixizumab
ucb pharmaceuticals
['ucbusa']
findings from subgroup analyses of the phase 3 mycaring study showed that #rozanolixizumab was effective across a broad range of patients with #mg, regardless of prior therapy use and disease duration. #aan2023 view: 
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments